XINSORB® Bioresorbable Scaffold launched its clinical application in Zhejiang province

Hangzhou, Zhejiang, China

The clinical application of Xinsorb Bioresorbable Scaffold in Zhejiang province was launched on 26th, Nov 2020 Hangzhou at Sir Run Run Shaw Hospital, with special thanks to the support of Academician Junbo Ge, Hospital Director Xiujun Cai and Chief Physician Guosheng Fu, 4 scaffold implantations accomplished at the same day.

Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, was established in 1994 through the donation of Sir Run Run Shaw, a well-known Hong Kong businessman and philanthropist, as well as matching funds from the Zhejiang government. SRRSH joined as a member of the Mayo Clinic Care Network in 2017.

About Xinsorb

The XINSORB® Scaffold is the first domestically made BRS by Chinese company. It is jointly researched by WEGO and a team led by Professor Junbo Ge, a member of the Chinese Academy of Sciences and a professor of Zhongshan Hospital affiliated to Fudan University.

The scaffold is composed of poly‑L‑lactic acid (PLLA) as its backbone. Poly‑D‑L‑lactic acid mixed with PLLA is coated on the scaffold surface, containing sirolimus and controlling its elution. It will be completely degraded and absorbed within 2 to 3 years after in-human stenting.

You may be interested